Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 12, 1997, Pages 2797-2799

  Piscitelli, Stephen C ^a   Figg, William D ^b   Hahn, Barbara ^c   Kelly, Grace ^c   Thomas, Steven ^d   Walker, Robert E ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CLINICAL ARTICLE; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA; NOTE; PRIORITY JOURNAL; VERTIGO;

EID: 0030784668     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.12.2797     Document Type: Note

References (21)

1. Ball, S. C., K. A. Sepkowitz, and J. L. Jacobs. 1997. Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review. Am. J. Gastroenterol. 92:169-170.
2. Chen, T.-L., G. B. Vogelsang, B. G. Petty, R. B. Brundrett, D. A. Noe, G. W. Santos, and O. M. Colvin. 1989. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metah. Dispos. 17:402-405.
3. D'Argenio, D. Z., and A. Schumitzky. 1990. ADAPT II user's guide. Biomedical Simulations Resource, University of Southern California, Los Angeles.
4. Doherty, G. M., J. C. Jensen, H. R. Alexander, C. M. Buresh, and J. A. Norton. 1991. Pentoxyfylline suppression of tumor necrosis factor gene transcription. Surgery 110:192-198.
5. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
6. Heney, D., D. R. Norfolk, J. Wheeldon, C. C. Bailey, I. J. Lewis, and D. L. Barnard. 1991. Thalidomide treatment for chronic graft-versus-host disease. Br. J. Haematol. 78:23-27.
7. Huupponen, R., and K. Pyykko. 1995. Stability of thalidomide in human plasma. Clin. Chem. 41:1199.
8. Jacobson, J. M., J. S. Greenspan, J. Spritzler, N. Ketter, J. L. Fahey, J. B. Jackson, L. Fox, M. Chernoff, A. W. Wu, L. A. MacPhail, G. L. Vasquez, and D. A. Wohl. 1997. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N. Engl. J. Med. 336:1487-1493.
9. Jusko, W. J. 1992. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (ed.), Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Applied Therapeutics, Inc., Vancouver, Wash.
10. Kluken, N., and W. Wente. 1974. Indications for thalidomide therapy for leprosy. Int. J. Dermatol. 13:20-25.
11. Makonkawkeyoon, S., R. N. Limson-Pobre, A. L. Moreira, V. Schauf, and G. Kaplan. 1993. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90:5974-5978.
12. Moreira, A. L., E. P. Sampaio, A. Zmuidzinas, P. Frindt, K. A. Smith, and G. Kaplan. 1993. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J. Exp. Med. 177:1675-1680.
13. Reyes-Teran, G., J. G. Sierra-Madero, V. Martinez del Cerro, H. Arroya-Figueroa, A. Pasquetti, J. J. Calva, and G. M. Ruiz-Palacious. 1996. Effects of thalidomide on HIV wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10:1501-1507.
14. Sampaio, E. P., E. N. Sarno, R. Galilly, Z. A. Cohn, and G. Kaplan. 1991. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173:699-703.
15. Schumacher, H., D. A. Blake, and J. R. Gillette. 1968. Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160:201-211.
16. Sharpstone, D., A. Rowbottom, M. Nelson, and B. Gazzard. 1995. The treatment of microsporideal diarrhea with thalidomide. AIDS 9:658-659. [Letter.]
17. Simmons, B. R., R. M. Lush, and W. D. Figg. 1997. A reverse phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum. Anal. Chim. Acta 17802:1-8.
18. Vicente, T., A. Ortega, P. Munoz, M. D. Diaz, and E. Bouza. 1993. In vitro activity of thalidomide against Mycobacterium avium complex. Arch. Intern. Med. 153:534. [Letter; comment.]
19. Walker R. E., K. M. Spooner, G. Kelly, R. V. McCloskey, J. N. Woody, J. Falloon, M. Baseler, S. C. Piscitelli, R. T. Davey, M. A. Polis, J. A. Kovacs, H. Masur, and H. C. Lane. 1996. Inhibition of immunoreactive tumor necrosis factor-α by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J. Infect. Dis. 174:63-68.
20. Weidle, P. J. 1996. Thalidomide for aphthous ulcers in patients infected with human immunodeficiency virus. Am. J. Health-Sys. Pharm. 53:368-372.
21. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Aiaike's information criterion in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.